In this meta-analysis, all relative literature was retrieved through the Embase and PubMed databases. Moreover, the Stata 12.0 software package was applied to calculate the pooled odds ratio (OR) of the 95% confidence interval (CI). A total of seven studies was identified to analyze the relation between ERCC1 and ERCC2 gene polymorphisms and pancreatic cancer risk. The results showed that ERCC2 rs13181 polymorphism was associated with pancreatic cancer (CC vs. AA: OR = 1.53, 95% CI = 1.24-1.90; AC vs. AA: OR = 1.06, 95% CI = 0.92-1.22; dominant model: OR = 1.16, 95% CI = 1.02-1.32; recessive model: OR = 1.39, 95% CI = 0.13-1.70). For ERCC1 rs3212986 polymorphism, a significant correlation with pancreatic cancer risk was found (TT vs. GG: OR = 2.33, 95% CI = 1.73-3.14; GT vs. GG: OR = 1.34, 95% CI = 1.11-1.63; dominant model: OR = 1.50, 95% CI = 1.25-1.80; recessive model: OR = 1.98, 95% CI = 1.50-2.62). A lack of association was found for ERCC1 rs11615 polymorphism (TT vs. CC: OR = 1.21, 95% CI = 0.93-1.56; CT vs. CC: OR = 1.02, 95% CI = 0.87-1.21; dominant model: OR = 1.43, 95% CI = 0.80-2.50; recessive model: OR = 0.99, 95% CI = 0.65-1.51).

中文翻译：

---

ERCC1和ERCC2基因多态性与胰腺癌风险的关联：一项荟萃分析。

在这项荟萃分析中，所有相关文献均通过Embase和PubMed数据库检索。此外，使用Stata 12.0软件包来计算95％置信区间（CI）的合并比值比（OR）。总共进行了七项研究，以分析ERCC1和ERCC2基因多态性与胰腺癌风险之间的关系。结果显示ERCC2 rs13181多态性与胰腺癌有关（CC vs.AA：OR = 1.53，95％CI = 1.24-1.90; AC vs.AA：OR = 1.06，95％CI = 0.92-1.22;优势模型： OR = 1.16，95％CI = 1.02-1.32；隐性模型：OR = 1.39，95％CI = 0.13-1.70）。对于ERCC1 rs3212986多态性，发现与胰腺癌风险显着相关（TT与GG：OR = 2.33，95％CI = 1.73-3.14; GT与GG：OR = 1.34，95％CI = 1.11-1.63;显性模型：OR = 1.50，95％CI = 1。25-1.80; 隐性模型：OR = 1.98，95％CI = 1.50-2.62）。发现缺少ERCC1 rs11615多态性的关联（TT与CC：OR = 1.21，95％CI = 0.93-1.56; CT与CC：OR = 1.02，95％CI = 0.87-1.21;主导模型：OR = 1.43，95％CI = 0.80-2.50；隐性模型：OR = 0.99，95％CI = 0.65-1.51）。